Precigen (NASDAQ:PGEN) Director Sells 1,086,153 Shares

by · The Cerbat Gem

Precigen, Inc. (NASDAQ:PGEN – Get Free Report) Director Randal Kirk sold 1,086,153 shares of the company’s stock in a transaction dated Wednesday, November 19th. The stock was sold at an average price of $4.47, for a total transaction of $4,855,103.91. Following the completion of the transaction, the director owned 7,434,384 shares in the company, valued at $33,231,696.48. This represents a 12.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Precigen Trading Down 0.5%

Shares of Precigen stock traded down $0.02 on Friday, hitting $3.88. 4,626,470 shares of the company traded hands, compared to its average volume of 4,540,987. The company has a current ratio of 4.04, a quick ratio of 3.95 and a debt-to-equity ratio of 2.22. The company has a market cap of $1.37 billion, a PE ratio of -2.79 and a beta of 1.71. The stock’s 50 day moving average price is $3.82 and its 200-day moving average price is $2.71. Precigen, Inc. has a 52 week low of $0.65 and a 52 week high of $5.22.

Precigen (NASDAQ:PGEN – Get Free Report) last released its quarterly earnings data on Thursday, November 13th. The biotechnology company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.03). The firm had revenue of $2.92 million for the quarter, compared to analysts’ expectations of $0.67 million. Precigen had a positive return on equity of 1,066.10% and a negative net margin of 3,912.92%. Equities research analysts predict that Precigen, Inc. will post -0.32 EPS for the current year.

Wall Street Analyst Weigh In

PGEN has been the topic of several research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Precigen in a research note on Wednesday, October 8th. HC Wainwright increased their target price on shares of Precigen from $8.50 to $9.00 and gave the stock a “buy” rating in a report on Friday, November 14th. Citigroup restated an “outperform” rating on shares of Precigen in a report on Tuesday, August 19th. JPMorgan Chase & Co. raised shares of Precigen from an “underweight” rating to a “neutral” rating in a research report on Friday, August 15th. Finally, Wall Street Zen lowered shares of Precigen from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $8.50.

Read Our Latest Research Report on PGEN

Institutional Trading of Precigen

A number of institutional investors have recently made changes to their positions in PGEN. Inspire Investing LLC acquired a new position in Precigen during the 1st quarter valued at about $350,000. MetLife Investment Management LLC purchased a new stake in shares of Precigen during the first quarter worth about $124,000. Adage Capital Partners GP L.L.C. grew its stake in shares of Precigen by 3.8% during the first quarter. Adage Capital Partners GP L.L.C. now owns 11,276,000 shares of the biotechnology company’s stock worth $16,801,000 after acquiring an additional 410,595 shares during the last quarter. Nuveen LLC acquired a new position in shares of Precigen during the first quarter valued at about $275,000. Finally, Mill Creek Capital Advisors LLC raised its position in shares of Precigen by 131.8% in the 1st quarter. Mill Creek Capital Advisors LLC now owns 255,000 shares of the biotechnology company’s stock valued at $380,000 after purchasing an additional 145,000 shares during the last quarter. Institutional investors and hedge funds own 33.51% of the company’s stock.

Precigen Company Profile

(Get Free Report)

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.

Featured Articles